Mini-ANP Peptides for Glaucoma via Corneal Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current natriuretic peptides, such as ANP, BNP, and CNP, are ineffective in treating ocular disorders like glaucoma due to their inability to penetrate the cornea, limiting their topical application and bioavailability.
Innovation Solution
Development of novel NPR-B agonists with improved bioavailability and chemical stability, specifically designed to activate the type B natriuretic peptide receptor (NPR-B), which can be used in ophthalmic compositions to treat glaucoma and other disorders mediated by natriuretic peptides or proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional natriuretic peptides (ANP, BNP, CNP) are used to treat ocular disorders, then they can activate NPR receptors, but they fail to penetrate the cornea effectively, limiting topical application and bioavailability
Solution Approach 1:
The patent modifies the molecular structure of natriuretic peptides by changing parameters such as molecular size, charge distribution, and chemical composition. Specifically, it creates mini-ANP (9-13 amino acids) and other truncated variants that alter the peptide's physical-chemical properties to enable corneal penetration while retaining NPR-B receptor binding capability. This structural parameter modification directly resolves the contradiction between receptor activation and corneal penetration.
Solution Approach 2:
The patent applies segmentation by truncating the full-length natriuretic peptides (ANP: 28 aa, BNP: 32 aa, CNP: 53 aa) into shorter fragments (mini-ANP: 9-13 aa, and other variants). This segmentation reduces the molecular size and improves permeability through the corneal barrier while maintaining the essential C-terminal residues necessary for NPR-B receptor activation, thus resolving the penetration issue without sacrificing receptor binding functionality.
2Duration of action of stationary object
If full-length natriuretic peptides are used, then they provide sustained receptor activation, but they have poor bioavailability and chemical stability in ocular tissues
Solution Approach 1:
The patent modifies key parameters of the peptide molecules including reducing molecular weight, optimizing the amino acid sequence to enhance chemical stability, and modifying the C-terminal region to improve receptor binding affinity. These parameter changes result in peptides with improved pharmacokinetic properties, enhanced bioavailability in ocular tissues, and increased chemical stability while maintaining sustained receptor activation.
Solution Approach 2:
The patent creates simplified copies or variants of the original natriuretic peptides by truncating them to essential functional fragments. These mini-peptides (mini-ANP, and other variants) are streamlined versions that retain the critical NPR-B binding motif at the C-terminus while removing unnecessary N-terminal sequences that compromise stability and bioavailability, thus achieving both short duration and high reliability.
3Ease of operation
If topical administration of natriuretic peptides is attempted, then it can directly treat ocular disorders, but the corneal barrier prevents effective penetration and drug delivery
Solution Approach 1:
The patent changes the physical-chemical parameters of the peptide molecules to optimize their interaction with the corneal barrier. By reducing molecular size, adjusting charge distribution, and modifying hydrophobicity through specific amino acid selections, the mini-peptides achieve enhanced corneal penetration while maintaining their ability to activate NPR-B receptors in the target tissue, thus enabling effective topical administration.
Solution Approach 2:
The patent segments the full-length peptides into shorter, more permeable fragments that can traverse the corneal barrier. The mini-ANP and other truncated variants are designed to pass through the corneal epithelium more effectively due to their reduced size and optimized structure, while still reaching the underlying tissues to activate the natriuretic peptide receptors, thereby enabling topical treatment of ocular disorders.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel NPR-B agonists effectively lower intraocular pressure and treat glaucoma by activating the NPR-B receptor with high specificity and potency, offering improved bioavailability and stability compared to traditional natriuretic peptides.
Implementation Method 1
The novel peptides provided herein bind to and activate the type B natriuretic peptide receptor (NPR-B)... increasing cyclic GMP production
Implementation Method 2
NPR-B... with guanylyl cyclase activity
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D- amino acid residues connected to one another via peptide bonds.